Michael L Hancock
Overview
Explore the profile of Michael L Hancock including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
31
Citations
1134
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Dalton J, Barnette K, Bohl C, Hancock M, Rodriguez D, Dodson S, et al.
J Cachexia Sarcopenia Muscle
. 2011 Oct;
2(3):153-161.
PMID: 22031847
BACKGROUND: Cachexia, also known as muscle wasting, is a complex metabolic condition characterized by loss of skeletal muscle and a decline in physical function. Muscle wasting is associated with cancer,...
12.
Smith M, Malkowicz S, Brawer M, Hancock M, Morton R, Steiner M
J Urol
. 2011 Oct;
186(6):2239-44.
PMID: 22014807
Purpose: Androgen deprivation therapy is associated with an increased fracture risk. In a recent phase III trial toremifene significantly decreased vertebral fractures in men on androgen deprivation therapy. Similar to...
13.
Saylor P, Morton R, Hancock M, Barnette K, Steiner M, Smith M
J Urol
. 2011 Jun;
186(2):482-6.
PMID: 21679977
Purpose: Androgen deprivation therapy for prostate cancer causes accelerated loss of bone mineral density and is associated with increased fracture risk. We evaluated risk factors associated with vertebral fractures among...
14.
Toremifene to reduce fracture risk in men receiving androgen deprivation therapy for prostate cancer
Smith M, Morton R, Barnette K, Sieber P, Malkowicz S, Rodriguez D, et al.
J Urol
. 2010 Aug;
184(4):1316-21.
PMID: 20723926
Purpose: Androgen deprivation therapy is associated with fracture risk in men with prostate cancer. We assessed the effects of toremifene, a selective estrogen receptor modulator, on fracture incidence in men...
15.
Marchese V, Connolly B, Able C, Booten A, Bowen P, Porter B, et al.
Phys Ther
. 2008 Jan;
88(3):341-50.
PMID: 18202079
Background And Purpose: Up to 38% of children receiving treatment for acute lymphoblastic leukemia (ALL) develop osteonecrosis, often without symptoms. Little is known about the association between the degree of...
16.
Pollack I, Jakacki R, Blaney S, Hancock M, Kieran M, Phillips P, et al.
Neuro Oncol
. 2007 Feb;
9(2):145-60.
PMID: 17293590
This study estimated the maximum tolerated dose (MTD) of imatinib with irradiation in children with newly diagnosed brainstem gliomas, and those with recurrent malignant intracranial gliomas, stratified according to use...
17.
Hoffer F, Hancock M, Hinds P, Oigbokie N, Rai S, Rao B
Pediatr Radiol
. 2007 Jan;
37(3):269-73.
PMID: 17203294
Background: Pleurodesis for end-of-life care has been used in adults for decades, but little is known about the usefulness of this technique in improving the quality of care for pediatric...
18.
Nething J, Ringwald-Smith K, Williams R, Hancock M, Hale G
JPEN J Parenter Enteral Nutr
. 2007 Jan;
31(1):53-7.
PMID: 17202441
Background: The negative health consequences of malnutrition in the pediatric oncology patient are well known. The purpose of this study was to determine the usefulness of body mass index (BMI)...
19.
Fouladi M, Blaney S, Poussaint T, Freeman 3rd B, McLendon R, Fuller C, et al.
Cancer
. 2006 Oct;
107(9):2291-7.
PMID: 17019740
Background: An open-label Phase II study of oxaliplatin was conducted to evaluate its safety and efficacy in children with recurrent or refractory medulloblastoma (MB), supratentorial primitive neuroectodermal tumors (SPNET), and...
20.
Gururangan S, Petros W, Poussaint T, Hancock M, Phillips P, Friedman H, et al.
Clin Cancer Res
. 2006 Mar;
12(5):1540-6.
PMID: 16533779
Purpose: A phase I trial of intrathecal Spartaject Busulfan (SuperGen, Inc., San Ramon, CA) was conducted in children with neoplastic meningitis following recurrent primary brain tumors to describe toxicities, estimate...